In a report released today, Ami Fadia from Needham maintained a Hold rating on ACADIA Pharmaceuticals (ACAD – Research Report). The company's shares closed last Thursday at $19.51. According to TipRanks.com, Fadia has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -7.3% and a 38.7% success rate. Fadia covers the Healthcare sector, focusing on stocks such as Harmony Biosciences Holdings, Intra-Cellular Therapies, and Avadel Pharmaceuticals. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for ACADIA Pharmaceuticals with a $29.70 average price target, a 52.3% upside from current levels.
https://www.tipranks.com/news/blurbs/needham-sticks-to-their-hold-rating-for-acadia-pharmaceuticals-acad?utm_source=advfn.com&utm_medium=referral
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Oct 2022 to Nov 2022 Click Here for more Acadia Pharmaceuticals Charts.
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Nov 2021 to Nov 2022 Click Here for more Acadia Pharmaceuticals Charts.